Looks like you clickedhttps://crweworld.com/article/news-provided-by-business-wire/3320141/pharmaessentias-besremi-ropeginterferon-alfa-2b-njft-now-recommended-as-a-preferred-first-line-cytoreductive-therapy-for-polycythemia-vera-in-updated-nccn-clinical-practice-guidelines-in-oncology-nccn-guidelines
If you do not want to visit that page, you can close this browser tab.
